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Abstract
Pain represents a significant source of morbidity, function loss, and decreased quality of life among people
living with HIV. The present study examined the associations among pain, pain treatment, and ARV adherence
among indigent, HIV-positive substance abusers. Participants were recruited via targeted sampling strategies,
and completed a one-time computer-assisted personal interview. ANOVA and chi-square tests were used to
analyze differences in demographics, health and psychological status, health behaviors, by pain and pain
treatment status; a multivariate logistic regression model was constructed to examine the contribution of pain/
treatment status to recent ARV adherence. Results indicated that those with untreated pain had lower odds of
achieving gold-standard 95% ARV adherence as compared to the pain-free and treated pain groups; higher
substance dependence symptoms were also associated with significantly lower odds of 95% ARV adherence.
Findings suggest that pain management is critical to the health of people living with HIV, specifically those
with high levels of co-morbid health and psychological problems. The prevalence of untreated pain was
elevated among this group, and contributed to reduced ARV adherence. Providers of clinical care to disad-
vantaged HIV-positive patients should emphasize routine assessment and appropriate treatment of pain in order
to provide comprehensive HIV care.
Introduction
Pain is common among people living with HIV, withprevalence estimates indicating that some 40–80% of
ambulatory HIV-positive patients endorse recent, clinically
significant pain.1–4 The etiology of pain among HIV-positive
individuals is varied, and includes infection-related inflam-
matory responses, secondary complications of progressive
HIV disease, as well as adverse effects of treatment with
antiretroviral (ARV) medications.5 Sensory neuropathy, for
example, has been estimated to affect 40–60% of treated
HIV-positive individuals,6 and often results in moderate to
severe pain. Regardless of etiology, the experience of pain
represents a significant source of morbidity, function loss,
and decreased quality of life among individuals living with
HIV,5,7,8 and has been associated with elevated levels of
psychological distress, including depression, anxiety, and
panic disorder, as well as greater HIV-related illness bur-
den.5,8–10 Despite these indicators, recent literature suggests
that pain is often under-recognized and under-treated in
clinical care for HIV-positive individuals.11,12
Many HIV-positive individuals suffer from co-morbid
mood disorders and/or substance abuse problems,3 and pain
management among these patients can present special chal-
lenges.12 In particular, the risk for medication misuse may
be heightened,13 and patients may require close monitoring;
likewise, the under-treatment of pain may lead to aberrant
drug-seeking behaviors.10 Despite these challenges, balanced
and appropriate pain management among vulnerable HIV
patients is critical to both individual and public health.7 A
small but emerging body of literature suggests that pain ex-
perience among HIV-positive patients is associated with
poor ARV adherence and reduced attendance at HIV-related
care visits,2,3,14 both of which are key behavioral components
of disease management to achieve viral suppression and
prevent onward transmission.15,16 Although a handful of
other studies has shown no link between pain and ARV
treatment adherence,1,13 the dearth of research on this topic
precludes consensus.
The purpose of this report is to examine the role that pain
and its corresponding treatment may play in vulnerable pa-
tients’ behavioral repertoires for HIV disease management.
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We recently documented substantial levels of ARV non-
adherence, as well as the illicit diversion (selling and trading)
of ARVs, among indigent substance abusing HIV-positive
patients in South Florida.17 Prior research has not adequately
examined the potential contribution of pain to these types of
health risk behaviors, and to our knowledge, existing studies
have been limited in investigating the influence of pain
treatment as a potentially important moderator of these re-
lationships. This article explores the associations of pain,
pain treatment, ARV adherence, and diversion among a large,
diverse sample of socioeconomically disadvantaged HIV-




Data were drawn from a large epidemiologic study de-
signed to examine the patterns and predictors of ARV di-
version among drug-involved people living with HIV in
South Florida. Due to the focus on ARV diversion, we re-
cruited a highly vulnerable sample of indigent HIV-positive
substance users likely to have exposure to ARV street mar-
kets. Study eligibility criteria were: age 18 or older; cocaine
or heroin use 12 or more times in the prior 3 months; docu-
mented HIV + status; and current ARV prescription. In ad-
dition, diverters endorsed at least one occasion of ARV
diversion in the prior 3 months.
Study recruitment
The study utilized targeted sampling techniques to guide
recruitment.18 Study investigators identified specific geo-
graphic areas for recruitment based on publically available
HIV prevalence and poverty-level indicator data. Initial re-
cruitment efforts targeted the communities to the north of
downtown Miami that are intersected by the highest rates of
HIV/AIDS19 and highest poverty indices in Miami-Dade
County. Over the life of the study, recruitment areas were
expanded based on information from community key infor-
mants in the target areas (including treatment professionals,
community outreach workers, HIV service providers, and
street-level drug users). Professional field staff used direct
outreach to distribute study information cards and flyers in a
variety of street venues and community-based HIV service
organizations within the identified target areas.
Study procedures
Potential participants were given information about the
project, and were asked to participate in telephone screening
for eligibility. Those meeting eligibility requirements were
scheduled for an appointment at the field site, where they
were re-screened by a research staff member. After eligibility
was confirmed on-site, informed consent procedures were
completed. 503 individuals were ultimately enrolled into the
study; by design, we included approximately equal numbers
diverting their ARV(s) (n= 251) and not (n= 252). Participants
completed a single, standardized interviewer-administered
questionnaire, which took approximately 1 h. Participants
were paid a $30 stipend for their time and travel costs to
complete the interview. Research staff completed the re-
quirements for National Institutes of Health (NIH) web-based
certification for protection of human subjects, and study pro-
tocols were subject to regular review by the University In-
stitutional ReviewBoard. A Certificate of Confidentiality from
the National Institutes of Health was obtained and a copy was
offered to participants.
Data collection and measures
Trained, bilingual research staff conducted computer-
assisted personal interviews (CAPI) in either English or
Spanish, according to the participant’s language preference.
The Global Appraisal of Individual Needs (GAIN, v. 5.4)20
was the primary data collection instrument. The GAIN cap-
tures information on demographics, physical and mental
health status, including DSM-IVR depression and anxiety
measures, substance use and DSM-IVR dependence, and
sexual risk behaviors, and has established reliabilities.
Standardized instruments also assessed HIV diagnosis/treat-
ment history,21 ARV adherence,22 and a newly developed
instrument assessed ARV diversion.
Demographic information gathered on study participants
included age, race/ethnicity, gender, and years since ini-
tial HIV diagnosis. As an indicator of economic need, we
assessed food and housing insecurity with a single item
adapted from a validated life stress scale.23 ‘‘In the 3 months
prior to interview, did you go without food, housing, or other
necessities because you did not have the money?’’
Health status was measured by five items. HIV-related
health status was assessed by self–report of: (1) most recent
CD4 count, and (2) most recent viral load. For the present
analysis, viral load was dichotomized into undetectable
versus not. Pain was assessed using a single item adapted
from the Health Distress Scale of the GAIN instrument.
Participants were asked, ‘‘During the past 90 days, have you
had a lot of physical pain or discomfort?’’ A separate item
queried related treatment: ‘‘Are you currently prescribed any
pain medication?’’ If appropriate, participants were permit-
ted to endorse multiple medications. Finally, we assessed
other medical diagnoses among the target sample, excluding
HIV. This included a range of chronic and acute health
conditions; participants were instructed to endorse all current
medical diagnoses.
Mental health subscales in the GAIN are based on DSM-
IVR criteria: nine items assess depression symptoms, and
twelve items assess anxiety symptoms over a 12-month
period.20,24 In all cases, higher scores indicate greater
problem severity. Alpha reliability coefficients for the de-
pression and anxiety scales were 0.87 and 0.88, respec-
tively. A separate item queried recency of depression and
anxiety symptoms: ‘‘When was the last time, if ever, you
had any of those significant nerve, mental or psychological
problems that we just talked about?’’ To obtain a measure of
current psychological distress, we dichotomized this vari-
able into ‘‘within the past month’’ or ‘‘not within the past
month.’’
Substance dependence in the past month was assessed
using DSM-IVR criteria, which consists of seven items
measuring drug problem severity (e.g., using more or longer
than intended, withdrawal problems). The present analysis
examined past month dependence symptom count as a
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continuous variable. The alpha reliability coefficient for the
DSM-IVR dependence scale was 0.85.
Participants self-reported ARV adherence in the past 7
days using the AIDS Clinical Trials Group instrument;22
information was gathered on total doses prescribed and total
doses missed in the past week. ARV doses taken were
computed and divided by total doses prescribed to generate
an adherence percentile score. For this analysis, this variable
was dichotomized into ‘‘95% + ’’ or ‘‘< 95%’’. This cut-point
was utilized in order to examine the proportions meeting the
current gold-standard for HIV medication adherence. ARV
diversion was measured by the following item: ‘‘When was
the last time, if ever, that you sold or traded any of your HIV
medications to another person for any reason?’’ For the
present analysis, this variable was dichotomized into ‘‘within
the past month’’ or ‘‘not within the past month’’.
Data analysis
Data from the interview questionnaires were analyzed
using SPSS for Windows, Version 21.25 The primary inde-
pendent variable of interest was recent pain and its associated
pharmacological treatment. We constructed three analytic
groups from the data: (1) pain-free: those individuals reporting
no pain in the past 90 days; (2) pain/untreated: individuals
reporting pain in the past 90 days and denying a current pain
medication prescription; and (3) individuals endorsing both
90-day pain and a current prescription for pain medication.
Descriptive statistics were calculated to describe the sample
in terms of pain and treatment status. ANOVA and Chi-
square tests were utilized to examine differences in socio-
demographics (age, gender, race, food/housing insecurity,
years HIV diagnosed); health status (CD4, viral load, other
medical conditions); psychological status (depression, anxi-
ety, current psychological problems, substance dependence),
and health behavior domains (ARV adherence, ARV diver-
sion) by pain and pain treatment status. Post-hoc Bonferroni
tests were computed to identify specific group differences for
significant ANOVA main effects.
Subsequently, a multivariate logistic regression model was
constructed to examine the potential contribution of pain/
treatment status to past week ARV treatment adherence,
while controlling for all variables displaying significant as-
sociations in the initial bivariate analyses. To reduce the
potential for multi-collinearity among our independent vari-
ables in the regression analysis, we included only the recency
measure of past month psychological distress and eliminated
past year symptom counts. For the regression analysis, 95%
percent ARV adherence was the outcome of interest and was
treated as a dichotomous variable. Variables were entered
simultaneously into the logistic regression model.
Results
The median age of the sample was 46 years; 59.4% were
male. More than three-quarters (81.4%) of study participants
had monthly incomes below $1000, and 39.2% reported
homelessness in the prior 3 months. Self-reported ARV ad-
herence in the past week was 95% or better among 54.1% of
participants (data not shown).
The prevalence of recent pain among this sample of indi-
gent HIV-positive substance users was 51.3%. Of those en-
dorsing pain, 41.5% indicated no current prescription for
pharmacotherapy. Among those who reported medication
treatment, 48.3% were prescribed an opioid, 39.1% a non-
steroidal anti-inflammatory drug (NSAID), and 21.9% indi-
cated another type of prescribed pain medication (data not
shown). Participants could endorse multiple prescription
types.
As shown in Table 1, pain experience and treatment status
were associated with a number of health and psychosocial
problems in this vulnerable sample. In terms of demograph-
ics, food/housing insecurity was more prevalent among both
pain groups (treated and untreated) compared to the pain-free
(v2 = 9.48; p= 0.009). No significant differences in HIV-
related health status were observed between the groups.
Nearly three-quarters of the sample (74.6%) indicated di-
agnosis with at least one other medical condition (excluding
HIV), and the mean number of health diagnoses in the sample
was 2.2 (data not shown). The highest prevalence diagnoses
included high blood pressure (31.2%), neuropathy (24.9%),
high cholesterol (22.5%), sleep disorders (21.3%), and ar-
thritis (20.3%). The presence of pain and its corresponding
treatment status were associated with other diagnosed health
problems endorsed by the sample. Higher illness burden was
associated with pain experience (F = 61.0; p = 0.000), as both
pain groups had significantly higher numbers of medical di-
agnoses than the pain-free group. Patients receiving pain
treatment also reported significantly more medical diagnoses
than their nontreated counterparts ( p = 0.000).
Analyses revealed disparities in mental health functioning
associated with pain and treatment status. In this regard, both
pain groups (treated and untreated) displayed significantly
higher levels of psychological distress when compared with
their pain-free counterparts, including past year symptoms
of depression (F = 34.3; p = 0.000) and anxiety (F= 33.7;
p = 0.000). Past month psychological symptoms were also
more prevalent among those with pain (v2 = 35.1; p = 0.000),
regardless of treatment status. Substance dependence symp-
toms in the prior month were elevated among those with
untreated pain compared to both the pain-free and treated
pain groups (F = 14.1; p = 0.000).
Pain was also associated with poorer disease management,
as indicated by ARV diversion and adherence. Nearly 40% of
those with untreated pain endorsed diversion of their ARV
medications in the past month, which was a significantly
higher proportion than either the pain-free or treated pain
groups (v2 = 6.62; p= 0.04). Past week ARV treatment ad-
herence levels were also reduced among HIV + individuals
with pain. The pain-free group displayed a higher likelihood
of achieving 95% medication adherence than either pain
group, regardless of treatment status (v2 = 11.81; p= 0.003).
Table 2 presents the results of the multivariate logistic
regression model examining the impact of food and housing
insecurity, pain and treatment status, other medical diag-
noses, past month psychological problems, past month sub-
stance dependence symptoms, and past month ARV
diversion on recent ARV adherence.
In the multivariate model, pain/treatment status, substance
dependence symptoms, and ARV diversion demonstrated
significant associations with ARV adherence. Those with
untreated pain had 42% lower odds of achieving 95% med-
ication adherence in the past week compared with the pain-
free ( p = 0.043). Substance dependence symptoms adversely
affected ARV adherence as well, with 11% lower odds of
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95% adherence per symptom endorsed ( p = 0.007). ARV
diversion displayed a strong association with adherence;
endorsement of past month HIV medication diversion re-
sulted in 74% lower odds of achieving 95% adherence
( p = 0.000).
Discussion
Pain is estimated to affect some 30% of adults in the US,
making it one of the most frequently occurring health dis-
orders in the nation.26,27 Among indigent, HIV-positive
substance abusers in South Florida, the present study docu-
mented recent pain prevalence of 51.3%. Although elevated
with respect to the general population, this finding is in line
with prior research on HIV-positive patients, which has
gauged pain prevalence to be between 40% and 80%.1–4 Our
data confirm that pain is an exceedingly common co-morbid
health condition among HIV-positive individuals, including
the non-elderly and those treated in an era of ARVs with
lower side effect profiles.
Although this study did not gather information on pain
intensity or duration, prescribed pharmacotherapy to treat
pain was modest, with 41.5% of those endorsing pain being
untreated. Pharmacotherapy for pain was more likely for
those with more diagnosed medical conditions; nevertheless,
those with untreated pain reported 2.4 medical diagnoses on
average, not including HIV infection. These data would ap-
pear to indicate substantial levels of physical health co-
morbidities among this vulnerable sample. Opioid therapy
was most common among those prescribed pharmacotherapy
at 48%, followed closely by NSAIDs at 39%. The relatively
common selection of non-opioid medications may reflect
Table 1. Sample Characteristics by Past 90-Day Pain and Treatment Status Among Indigent












Age, mean (SD) 46.9 (7.4) 46.8 (8.0) 45.3 (7.9) 2.50 0.08
Male gender, n (%) 79 (52.3) 64 (59.8) 156 (63.7) 5.01 0.08
African American, n (%) 101 (66.9) 71 (66.4) 169 (69.0) 0.32 0.85
Food/housing insecurity, n (%) 71 (47.0) 57 (53.3) 90 (36.7) 9.48 0.00
Years HIV diagnosis, mean (SD)a 13.5 (7.3) 13.7 (7.4) 12.9 (7.2) 0.56 0.57
Health status
Current CD4, mean (SD)a 480.3 (293.9) 449.5 (264.0) 480.1 (285.3) 0.46 0.63
Undetectable viral load, n (%)a 65 (49.2) 48 (49.0) 103 (46.2) 0.39 0.82
Other medical conditions, mean (SD) 3.4 (2.4) 2.4 (2.2) 1.2 (1.4) 61.05 0.00
Psychological status
Depression symptoms past yr., mean (SD) 6.3 (2.6) 6.4 (2.7) 4.3 (3.0) 34.34 0.00
Anxiety symptoms past yr., mean (SD) 5.8 (3.5) 5.9 (3.6) 3.3 (3.3) 33.70 0.00
Psychological symptoms past mo., n (%)a 122 (80.8) 87 (81.3) 138 (56.6) 35.13 0.00
Dependence symptoms past mo., mean (SD) 3.4 (2.5) 4.5 (2.5) 3.0 (2.4) 14.14 0.00
Health behaviors
95% ARV adherence past week, n (%) 77 (51.0) 45 (42.1) 150 (61.2) 11.84 0.00
ARV diversion past month, n (%) 38 (25.2) 42 (39.3) 68 (27.8) 6.62 0.04
aN= 502; N = 464, N = 453, N = 502
Table 2. Multivariate Logistic Regression Model Predicting 95% ARV Adherence Among
HIV + Substance Abusers in South Florida (N = 502)
B Odds ratio 95% CI Sign. level
Demographics
Food/housing insecuritya - 0.066 0.936 (0.628, 1.40) 0.744
Health status
Paina
Untreated - 0.538 0.584 (0.346, 0.984) 0.043
Treated - 0.492 0.611 (0.372, 1.01) 0.052
No. of other medical conditions 0.037 1.037 (0.939, 1.15) 0.469
Psychological status
Psychological symptoms past mo.a - 0.199 0.820 (0.526, 1.28) 0.380
No. of dependence symptoms past mo. - 0.113 0.893 (0.822, 0.970) 0.007
Health behaviors
ARV diversion past montha - 1.322 0.266 (0.172, 0.413) 0.000
aReference category is ‘no’.
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caution among health care providers and prescribers treating
a population with known substance abuse issues.28
Among our vulnerable sample of socioeconomically dis-
advantaged HIV-positive substance users, pain likely arose
from multiple sources, including aging, long-standing par-
ticipation in street lifestyles that entail drug use and exposure
to violence, the presence of multiple chronic health condi-
tions, as well as poverty-driven limitations on health care
access and basic subsistence needs. Our bivariate analyses
demonstrated that food and housing insecurity were signifi-
cantly associated with pain endorsement. This finding is
consistent with the notion that environmental living condi-
tions, in this case inadequate access to food and safe housing,
engender circumstances that may cause, exacerbate, or per-
petuate pain. In this regard, prior research has linked housing
instability to both high pain prevalence and multiple barri-
ers to care.28–32
Consistent with prior studies,33–35 bivariate analyses
found that pain endorsement was strongly associated with
psychological distress among this sample of substance us-
ers. Individuals with pain, regardless of treatment status,
exhibited higher symptom levels for both depression and
anxiety, compared to the pain-free. Depression and pain
have often been linked in the scientific literature and are
known to share biological pathways,36 which would indi-
cate that simultaneous treatment approaches may be re-
quired for improvement.
Our finding that untreated pain is associated with more
problematic substance use may indicate that individuals
with pain are attempting to self-medicate through illicit drug
use, a phenomenon that has been documented by other re-
searchers.34 Alternatively, it may be that HIV-positive indi-
viduals who display more problematic substance use are less
likely to receive pain treatment, possibly due to prescriber
reluctance, or the patients’ inability to comply with ap-
pointment schedules or other monitoring requirements. Ad-
ditionally, disadvantaged HIV-positive patients with heavy
substance use may not seek formal treatment for pain, par-
ticularly if they remain enmeshed in street lifestyles that limit
their access to routine care.
One of the key findings of this study is the demonstration
of a graduated improvement in recent ARV adherence cor-
responding to pain and treatment status. The pain-free group
reported the highest adherence, with 61% achieving gold-
standard 95% adherence, followed by those with treated pain
at 51%, and untreated pain at 42%. Importantly, untreated
pain retained a significant direct effect on ARV adherence in
the multivariate analysis, even when controlling for other
significant factors.
In the present study, participants were required to have
an ARV prescription as an eligibility criterion, which in-
dicates that they were seeing their HIV care provider reg-
ularly in order to maintain their access to ARVs. Within
the context of HIV care visits, routine assessment for
pain appears to be warranted. Many non-opioid pharma-
cotherapies present little risk for misuse and abuse, and
regular assessments of pain type, severity, and functional
impairment may indicate the need for treatment. Treating
pain adequately may provide a mechanism to support
improved ARV adherence, which can be especially critical
for patients with high levels of competing needs who often
struggle with medication regimen compliance. Improving
physical function and quality of life through effective pain
management may assist in this regard.
This study has several limitations that should be consid-
ered when interpreting the results. First, the sample is not
representative of HIV-positive patients. Given the study’s
focus on ARV diversion, recruitment was targeted to enroll
indigent, substance abusing individuals who were located in
specific geographic areas where the phenomenon of interest
was occurring. This limits generalizability of the findings to
other HIV-positive patient populations. A second limitation
involves reliance on self-report data. It is possible that recall
problems and social desirability biases influenced participant
responses to the interview items; nevertheless, the high levels
of substance use, ARV diversion, and low ARV adherence
reported suggest that participants did not substantially under-
report these behaviors. Measures of CD4 and viral load were
also obtained from participant self-report; recall problems
may have impacted the reliability of these measures and
limited our ability to detect relationships in the data. An
additional limitation is the cross-sectional nature of the in-
terview data that were gathered; the lack of temporal data
limits our ability to demonstrate causal relationships among
the key variables. Finally, our measures of pain were limited,
and no information was collected on pain intensity, duration,
or etiology, so it is not definitive that medication therapy
would have been indicated; similarly, it is unknown if pa-
tients were receiving alternative therapies for pain.
Our findings point to the need for further research on pain
severity, functional impairment, ARV adherence, and di-
version among vulnerable HIV-positive patients. In particu-
lar, future research may investigate the extent to which ARV
diversion is undertaken with the goal of self-medication; that
is, to gain access to analgesic medications through illicit
sources. Investigation of the influence of untreated pain on
positive coping skills is also warranted, as pain may render
individuals less motivated to treat their HIV disease and
lower compliance with ARV medication regimens.
We believe that this study provides compelling evidence
that pain assessment and management warrant more attention
among health care providers who serve disadvantaged HIV-
positive patients. Given the competing needs of these
vulnerable patients and limited access to both routine and
specialized medical care,37 the assessment and treatment of
pain may fall to HIV care providers, particularly in locations
that lack wrap-around services for HIV-positive individuals.
The association of untreated pain with ARV non-adherence
would appear to be clinically significant, and vulnerable
patients may benefit from provider-initiated assessment and/
or discussion of pain experience and its impact on the man-
agement of HIV. Raising provider awareness of pain as a
significant risk factor for ARV non-adherence may lead to the
implementation of other clinical intervention approaches for
the treatment of pain among disenfranchised HIV-positive
individuals as well.
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